The net profit of 9 traditional Chinese medicine companies doubled, and Dong'e Ejiao became the "growth king"

With the opening of the A-share 2021 annual report disclosure, the performance of many traditional Chinese medicine companies has also surfaced
.
Up to now, more than 40 traditional Chinese medicine companies have disclosed their performance, and nearly 70% are pre-happy
.
Among them, 4 companies such as Pien Tze Huang and Kang Enbei have a net profit of over 2 billion yuan; from the perspective of growth, 9 companies have doubled their net profit, Dong'e Ejiao has become the "growth king", and *ST Kangmei has turned a loss after a huge loss of more than 20 billion yuan.
Profit
.
In addition, there are 4 first losses
.
Industry analysts pointed out that although the Chinese medicine sector has been adjusted recently, the long-term positive trend remains unchanged.
Driven by factors such as policies, consumption upgrades, and valuation advantages, the superimposed annual report disclosure has entered an intensive period, and Chinese medicine companies with excellent performance will be prepared.
attention
.
As of the close on March 2, many traditional Chinese medicine stocks such as Zhongsheng Pharmaceutical and Longjin Pharmaceutical were trading at their daily limit, while Kangyuan Pharmaceutical, Lingrui Pharmaceutical, and Yabao Pharmaceutical were among the top gainers
.
4 net profit exceeded 2 billion! Jichuan, Qizheng, Hongri.
.
.
Traditional Chinese medicine companies with outstanding performance and net profit of over 500 million As of now, more than 40 traditional Chinese medicine companies have disclosed their performance (annual reports, express reports, and forecasts), and nearly 70% are positive
.
Among them, four companies including Tasly and Pien Tze Huang have a net profit of over 2 billion yuan, and Jichuan Pharmaceutical, Qizheng Tibetan Medicine and Hongri Pharmaceutical also showed double-digit growth
.
It is worth mentioning that there are only 2 traditional Chinese medicine companies with a net profit of over 2 billion yuan in 2020
.
Red Sun Pharmaceutical Revenue was 7.
741 billion yuan, up 19.
32% year-on-year Net profit was 688 million yuan, up 20.
03% year-on-year A few days ago, Red Sun Pharmaceutical announced its 2021 performance report, with both revenue and net profit hitting new highs
.
Hongri Pharmaceutical said that the company strengthened resource allocation and business synergy, actively deployed and seized market opportunities, and continued its good business momentum.
Among them, the traditional Chinese medicine formula granule business continued to strengthen the national production capacity layout, and continued to improve market coverage and stock market penetration.
Revenue and profit achieved a significant increase over the same period of the previous year; the sales volume of Xuebijing injection, the main product of the finished drug business, grew steadily; the raw and auxiliary drug business, benefiting from the restructuring of the international pharmaceutical industry chain, the company seized market opportunities and actively promoted product optimization , to promote the increase of overseas market share, and revenue increased year-on-year in 2020
.
Entering 2022, there are frequent reports of good news from Red Sun Pharmaceutical
.
The company's enoxaparin sodium injection was approved as a generic category 4, which is regarded as over-evaluation
.
According to data from Minet.
com, in 2020, the sales of terminal enoxaparin sodium injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 2 billion yuan, and the first half of 2021 was year-on-year.
An increase of more than 20%.
At present, a total of 10 companies have production approvals for this product, and Hongri Pharmaceutical is the third company that has passed the review
.
Prior to this, the company's product under development, Picromide B for injection, obtained the US FDA Fast Track qualification.
This product is currently the only dual-target bacterial pathogen-related molecular antagonist in the world.
It is developed with LPS and CpGDNA as dual targets.
of sepsis drugs
.
Jichuan Pharmaceutical’s revenue was 7.
631 billion yuan, a year-on-year increase of 23.
77%, and its net profit was 1.
664 billion yuan, a year-on-year increase of 30.
31%.
Regarding the sharp rise in performance, Jichuan Pharmaceutical said that, on the one hand, with the effective control of the epidemic, medical institutions have gradually resumed normal operations.
The adverse impact on the company's operations was gradually eliminated; on the other hand, the company's product revenue structure was further optimized and improved, and the sales of echelon products achieved rapid growth
.
In addition, the company actively strengthens the expansion of sales channels, actively promotes the development of blank markets and potential markets, and forms new increments
.
In February this year, Jichuan Pharmaceutical issued an announcement saying that the company's concentrated solution of magnesium sodium and potassium sulfate for oral use was approved as a 3-type imitation, becoming the first domestic imitation + the first over-evaluation enterprise of this product, and the company's first approved this year.
product
.
Up to now, Jichuan Pharmaceutical has 8 products for production and 2 supplementary applications for consistency evaluation are under review
.
In addition, since 2017, the company has a total of 5 new drugs approved for clinical use, of which 2 are 8 types of new Chinese patent medicines
.
9 doubles! Dong'e Ejiao has become the "growth king".
This Chinese medicine company with a huge loss of over 20 billion has turned around and its net profit has increased by more than 100%.
From the perspective of growth, the net profit of 9 Chinese medicine companies has doubled, and Dong'e Ejiao has increased by more than 800%.
Quickly became the "growth king", *ST Kangmei turned losses into profits after a huge loss of over 20 billion
.
In addition, there are 4 first losses
.
Dong'e Ejiao Net profit of 428 million to 475 million yuan, a year-on-year increase of 888% to 997% Dong'e Ejiao is expected to increase its net profit by more than 800% year-on-year in 2021, becoming the "growth king"
.
Dong-E-Ejiao said that the company adheres to consumer-centricity, focuses on customer growth and retention, accelerates product innovation, strengthens the transformation of scientific research results, and continuously releases brand productivity to achieve stable growth
.
In fact, in the semi-annual report, the company proposes countermeasures from five aspects of product research and development, channels, and industrial models for the risks faced by raw material supply and market demand, including building a research and development platform with industry influence from a single product to a product group.
, from a single OTC terminal to an omni-channel layout,
etc.
In addition, Dong'e Ejiao pointed out in the performance forecast that in the future, the company will actively respond to the call of the state to promote the inheritance, innovation and development of traditional Chinese medicine, and adhere to the guidance of becoming "the most trusted large-scale health enterprise in the field of Chinese nourishing and health care".
Demand-oriented, accelerate digital transformation and business model innovation; further promote "value reshaping, business reshaping, organizational reshaping, and spiritual reshaping", consolidate the market leadership of core products, extend existing brand categories, and focus on market and customer needs Provide solutions to enhance organizational capabilities for digital transformation and promote high-quality development of the company
.
Jianmin Group’s net profit is 318 million to 333 million yuan, an increase of 115% to 125% year-on-year.
Jianmin Group expects its net profit to exceed 300 million yuan in 2021.
The company’s performance growth is mainly due to the increase in revenue from the pharmaceutical industry.
In 2021, the company will increase advertising investment With market development efforts, product structure and marketing team building are optimized, and revenue from major OTC product lines and prescription drug product lines is increased.
It is expected that the revenue of the pharmaceutical industry will increase by more than 40% year-on-year in 2021
.
In January this year, Jianmin Group announced that the company's 1.
1 class of innovative traditional Chinese medicine drug Qirui Weishu Capsule was approved.
The launch of this product provides a new treatment option for chronic gastritis patients
.
Jianmin Group stated that the approval of Qirui Weishu Capsules will further enrich the company's product line in related therapeutic fields, which will help to enhance the core competitiveness and have a positive impact on the company's future development
.
It is understood that Qirui Weishu Capsule has entered the production stage and plans to enter the market in the near future
.
Conclusion In recent years, the state has continued to promote the development of the traditional Chinese medicine industry, which has led to a strong rally in traditional Chinese medicine stocks
.
From the end of last year to the beginning of this year, the traditional Chinese medicine sector continued to heat up, and many individual stocks took turns to set off the daily limit
.
Industry analysts pointed out that although the Chinese medicine sector has been adjusted recently, the long-term positive trend remains unchanged.
Driven by factors such as policies, consumption upgrades, and valuation advantages, the superimposed annual report disclosure has entered an intensive period, and Chinese medicine companies with excellent performance will be prepared.
attention
.
As of the close on March 2, many traditional Chinese medicine stocks such as Zhongsheng Pharmaceutical and Longjin Pharmaceutical were trading at their daily limit, while Kangyuan Pharmaceutical, Lingrui Pharmaceutical, and Yabao Pharmaceutical were among the top gainers
.
Source: Oriental Fortune.
com, company announcements, etc.
Note: The statistics are as of the close of market on March 2.
If there are any omissions, please correct me!